Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer(S1802) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (GI002) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Disease Registry for patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Open-label, Randomized Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First- Line Treatment of Subjects with Advanced Renal Cell Carcinoma (16145) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Randomized Study Evaluating the Efficacy and Safety of Canakinumab vs Placebo as Adjuvant Therapy in Subjects with Stages AJCC/UICC v. 8 II-IIIA and IIIB Completely Resected (R0) NonSmall Cell Lung C(17167) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab vs Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lympho III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Multicenter, Randomized, Open-label Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338- 063) (16238) III
Mary Beth WIlwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Pilot Study of Chemotherapy Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients (228-17) III
Mary Beth Wilwerding
Phone
402-991-8070
Fax
402-991-8850
A Placebo Controlled Trial of Adjuvant MK3475 in RCC Post Nephrectomy (MK3475-564) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Prospective Multicenter Non-interventional Study of Patients Receiving Palbociclib in Advanced Breast Cancer III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (S1500) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study Comparing PDR001, Debrafenib and Trametinib vs Placebo, Dabrafenib and Trametinib in Previously Untreated Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma (CPDR001F2301) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer with HER2 Amplification (S1613) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of AM0010 in Combination with Nivolumab vs Nivolumab Alone as Second Line Therapy in Subjects with Stage IV Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (17201) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma (EA6134) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double-Blind, Placebo Controlled Study of Pazopanib with or without Abexinostat in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (XYN-602) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Multicenter Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy (17058) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Study of Avelumab in Combination with Standard of Care Chemoradiotherapy vs Standard of Care Chemoradiotherapy in Front Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (B9991016) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study Comparing Venetoclax + Fulvestrant vs Fulvestrant In Women with Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of BBI-608 in Combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CanStem303C) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Combining Talimogene Laherparepvec (T-VEC) and MK-3475 (pembrolizumab) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy (S1607) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Efficacy and Safety of Lanreotide Autogel/Depot 120 mg plus BSC vs Placebo plus BSC for Tumor Control in Subjects with Well-Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (15079 A-US-52030-328) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members